XTX Topco Ltd Invests $331,000 in Tyra Biosciences, Inc. $TYRA

XTX Topco Ltd bought a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 34,601 shares of the company’s stock, valued at approximately $331,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TYRA. US Bancorp DE grew its stake in Tyra Biosciences by 50.5% during the 1st quarter. US Bancorp DE now owns 5,435 shares of the company’s stock valued at $51,000 after purchasing an additional 1,823 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Tyra Biosciences in the first quarter valued at approximately $84,000. Public Employees Retirement System of Ohio acquired a new position in Tyra Biosciences in the 2nd quarter worth approximately $177,000. Intech Investment Management LLC increased its holdings in Tyra Biosciences by 46.5% in the 2nd quarter. Intech Investment Management LLC now owns 19,919 shares of the company’s stock worth $191,000 after buying an additional 6,322 shares during the period. Finally, American Century Companies Inc. raised its position in Tyra Biosciences by 5.8% during the 1st quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock worth $218,000 after buying an additional 1,289 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Insiders Place Their Bets

In other news, Director Robert J. More sold 246,871 shares of the stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $20.25, for a total value of $4,999,137.75. Following the completion of the sale, the director owned 3,833,425 shares of the company’s stock, valued at $77,626,856.25. This represents a 6.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 15.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Thursday, November 6th. Oppenheimer reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Tyra Biosciences in a report on Wednesday, September 10th. Raymond James Financial assumed coverage on Tyra Biosciences in a research note on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Tyra Biosciences Stock Down 2.8%

TYRA opened at $21.50 on Friday. The company has a market cap of $1.15 billion, a PE ratio of -11.50 and a beta of 1.09. Tyra Biosciences, Inc. has a twelve month low of $6.42 and a twelve month high of $22.83. The company has a 50-day moving average price of $16.31 and a 200 day moving average price of $12.74.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, hitting the consensus estimate of ($0.50). As a group, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.